Literature DB >> 22949530

Achievement of cardiometabolic goals in aware hypertensive patients in Spain: a nationwide population-based study.

José R Banegas1, Auxiliadora Graciani, Juan J de la Cruz-Troca, Luz M León-Muñoz, Pilar Guallar-Castillón, Antonio Coca, Luis M Ruilope, Fernando Rodríguez-Artalejo.   

Abstract

Despite the importance of achieving cardiometabolic goals beyond blood pressure, in the health of hypertensives, no comprehensive assessment of these characteristics has been performed in whole countries. We studied in 2008-2010 a total of 11 957 individuals representative of the Spanish population aged≥18 years. Information on cardiometabolic characteristics was collected at the participants' homes, through structured questionnaires, physical examination, and fasting blood samples. A total of 3983 individuals (33.3%) had hypertension (≥140/90 mm Hg or current antihypertensive drug treatment), 59.4% were aware of their condition, 78.8% treated among those aware, and 48.5% controlled among those aware and treated (22.7% of all hypertensives). Of the aware hypertensives, 13.8% had a body mass index<25 kg/m2, 38.6% consumed <2.4 g/d of sodium, 19.3% were diabetic with 61% attaining goal hemoglobin A1c<6.5%, whereas 42.3% had hypercholesterolemia, with 38.1% reaching goal low-density lipoprotein<115 mg/dL. Only 30.7% of overweight patients received a prescription of specific method for weight loss, 17.4% of daily smokers were offered a smoking cessation strategy, and 15.8% of older patients were given a flu shot. Aware and unaware hypertensives showed a similar frequency of some lifestyle, such as adequate physical activity. In conclusion, in a European country with a well-developed, free-access healthcare system, achievement of many cardiometabolic goals among hypertensives is poor. Moreover, a serious deficiency in hypertension awareness and in the effectiveness of some lifestyle interventions among aware hypertensives is present. Greater effort is needed in the management of coexisting risk factors and on lifestyle medical advice to improve the cardiometabolic health of hypertensives.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22949530     DOI: 10.1161/HYPERTENSIONAHA.112.193078

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  24 in total

1.  Cost of poor adherence to anti-hypertensive therapy in five European countries.

Authors:  F S Mennini; A Marcellusi; J M Graf von der Schulenburg; A Gray; P Levy; P Sciattella; M Soro; G Staffiero; J Zeidler; A Maggioni; R E Schmieder
Journal:  Eur J Health Econ       Date:  2014-01-05

2.  Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries.

Authors:  Katherine T Mills; Joshua D Bundy; Tanika N Kelly; Jennifer E Reed; Patricia M Kearney; Kristi Reynolds; Jing Chen; Jiang He
Journal:  Circulation       Date:  2016-08-09       Impact factor: 29.690

Review 3.  Can the Treatment of Hypertension in the Middle-Aged Prevent Dementia in the Elderly?

Authors:  Antonio Coca; Eila Monteagudo; Mónica Doménech; Miguel Camafort; Cristina Sierra
Journal:  High Blood Press Cardiovasc Prev       Date:  2016-04-13

4.  Metabolic syndrome and Growth Differentiation Factor 15 in older adults.

Authors:  Adrián Carballo-Casla; Esther García-Esquinas; Antonio Buño-Soto; Ellen A Struijk; Esther López-García; Fernando Rodríguez-Artalejo; Rosario Ortolá
Journal:  Geroscience       Date:  2021-05-07       Impact factor: 7.581

5.  Effect of Olmesartan-Based Therapies on Therapeutic Indicators Obtained Through Out-of-Office Blood Pressure.

Authors:  Manuel Gorostidi
Journal:  Cardiol Ther       Date:  2015-06-13

6.  Do Hypertensive Individuals Who Are Aware of Their Disease Follow Lifestyle Recommendations Better than Those Who Are Not Aware?

Authors:  Yuna Kim; Kyoung Ae Kong
Journal:  PLoS One       Date:  2015-08-28       Impact factor: 3.240

7.  The burden of blood-pressure-related cardiovascular mortality in Mexico.

Authors:  Dora E Cortés-Hernández; Krista J Lundelin; Esteban Picazzo-Palencia; Juan J de la Cruz; José J Sánchez; José R Banegas
Journal:  Int J Hypertens       Date:  2014-02-10       Impact factor: 2.420

8.  Combination With Low-dose Dextromethorphan Improves the Effect of Amlodipine Monotherapy in Clinical Hypertension: A First-in-human, Concept-proven, Prospective, Dose-escalation, Multicenter Study.

Authors:  Wei-Hsian Yin; Pei Chen; Hung-I Yeh; Kuo-Yang Wang; Yi-Jen Hung; Wei-Kung Tseng; Ming-Shien Wen; Tao-Cheng Wu; Chau-Chung Wu; Shu-Meng Cheng; Jaw-Wen Chen
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

9.  Patients' beliefs regarding informed consent for low-risk pragmatic trials.

Authors:  Rafael Dal-Ré; Antonio J Carcas; Xavier Carné; David Wendler
Journal:  BMC Med Res Methodol       Date:  2017-09-18       Impact factor: 4.615

10.  Public preferences on written informed consent for low-risk pragmatic clinical trials in Spain.

Authors:  Rafael Dal-Ré; Antonio J Carcas; Xavier Carné; David Wendler
Journal:  Br J Clin Pharmacol       Date:  2017-06-11       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.